Hemostasis Global Clinical Trials Review, H1, 2016
“Hemostasis Global Clinical Trials Review, H1, 2016" provides an overview of Hemostasis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemostasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Benefits of report:
• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months
Read More Description @ http://www.marketintelreports.com/report/gdhc3209ctidb/hemostasis-global-clinical-trials-review-h1-2016
Report helps you in:
• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level
Companies mentioned in the report:
Baxter International Inc. Johnson & Johnson Novo A/S LAL Clinica Pesquisa e Desenvolvimento Ltda Takeda Pharmaceutical Company Limited ZymoGenetics, Inc. The Medicines Company Teva Pharmaceutical Industries Limited Omrix Biopharmaceuticals, Inc. Bristol-Myers Squibb Company
Request Sample Brochure Here @ http://www.marketintelreports.com/pdfdownload.php?id=gdhc3209ctidb
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
2711 Centerville Road, Suite 400,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemostasis Global Clinical Trials Review, H1, 2016 here
News-ID: 342715 • Views: 855
More Releases from MarketIntelReports
Study on Future Growth Drivers of the Cloud Integration Market
Cloud Integration or integration platform as a service (iPaaS) is one of the fast emerging forms of cloud computing services that are delivered to configure data with various application programs. These application programs range from enterprise risk management (ERM), customer relationship management (CRM), database management system (DBMS), and business process management to web conferencing, and emails, etc. Cloud integration services are especially designed to help organizations of all sizes to
Analysis of Variables Pushing the Expansion of the Workforce Management Market
Workforce Management is an integrated set of processes that an institution or organization uses to optimize the productivity of its employees on the individual, departmental, and entity-wide levels. This report identifies the Workforce Management market size in terms of value for the year 2014-2016, and forecast of the same for year 2021. It highlights potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges,
Study on Future Growth Drivers of the Blockchain Market
The blockchain technology market size is estimated to grow from USD 210.2 Million in 2016 to USD 2,312.5 Million by 2021, at a Compound Annual Growth Rate (CAGR) of 61.5% during the forecast period. In the report, 2015 is considered the base year, while the forecast period is 2016–2021. The objective of the report is to define, describe, and forecast the blockchain technology market on the basis of providers, applications, deployment
Glass Bonding Adhesives Market by End-Use Industry (Furniture, Electronics, Medi …
The use of adhesives and glues as a bonding agent between glass and other materials is increasing now a days. The glass bonding adhesives has a wide range of applications in automotive industry for bonding the glass in vehicles, manufacturing of water tanks and optical glasses, bonding of window glass to frame or structure etc. The selection of a suitable adhesive for proper bonding of glass depends upon various factors
More Releases for Trial
Clinical Trial Management System
According to a new market report published by Persistence Market Research “Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019” the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019. Request Report TOC @ https://www.persistencemarketresearch.com/methodology/3017
Paediatric Clinical Trial Conference - When designing a Paediatric clinical tria …
Press Release – 12.02.2018 When designing a Paediatric clinical trial, a paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Singapore Clinical Trial Market Analysis
Singapore has off late come to become the nucleus of clinical research activities in the Asia-Pacific region. The country is a natural hub for manufacturers and clinicians. It also possesses one of the best healthcare infrastructure networks in the entire region. Singapore is the third largest market in Asia for conducting clinical trials. The national government has been extremely supportive in developing clinical research activities and maintaining high immunization rates.
Clinical Trial Logistics
Clinical Trial Logistics 16th to 17th May 2011, Marriott Regents Park, London, United Kingdom. It currently costs just over £500 million ($800 million) to bring a new chemical to market and development timelines continue to fall in the 10-15 year range. A key reason for high R&D costs is due to logistical failures including failure to recruit patients on time. A way to avoid this is to move clinical trials
Clinical Trial Logistics
Announcing SMi's 5th annual… Clinical Trial Logistics conference 16th and 17th May 2011, Central London, UK www.smi-online.co.uk/2011logistics-london6.asp It currently costs just over £500 million ($800 million) to bring a new chemical to market and development timelines continue to fall in the 10-15 year range. A key reason for high R&D costs is due to logistical failures including failure to recruit patients on time. A way to avoid this is to move clinical